Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
SG CapTM, a Unique Immobilization Method Optimized for Multiplex Diagnostics, with Higher Sensitivity and Specificity Than Currently Available Technology_PCL, Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Introducing SG CapTM, a unique immobilization method optimized for multiplex diagnostics, with higher sensitivity and specificity than currently available technology...
Contact Yong U Kim
Participants
You
Email me a copy of this message

1. Summary

SG Cap™ is a molecule-capturing platform for studying molecular interactions, including drug-target pairs and protein-protein relationships.


SG Cap™ immobilizes compounds in their natural conformation without affinity tags or other chemical modification.

SG CapTM sol gel formula assembles into a three-dimensional network of pores that are connected by larger channels. The porous format significantly increases load capacity while interconnecting channels reduce diffusion distances compared to competing two-dimensional systems.

Samples flow through channels and are captured inside pores, where they float freely in their native conformations. Samples within the pores can be studied from all angles, while non-specific material easily washes away, reducing the signal-to-noise ratio.

SG CapTM is a unique immobilization method that exceeds the sensitivity and specificity thresholds of currently available technology.

2. Applications

Research purposes

SG CapTM immobilizes proteins, antibodies, chemicals and other molecules in their natural conformations without covalent modifications. Researchers can make any biochips necessary for research purposes

Multiplex diagnostic test kit

SG CapTM is used for multiplex diagnostic kits that screen blood samples for various diseases simultaneously

Identification of drug targets

SG CapTM can identify cellular targets for drugs. This technique can be used to identify target molecules for your library of known drugs or PD (pharmacodynamic) /PK (pharmacokinetic) – optimized compounds.

3. Market Feasibility

The IVD (In vitro diagnostics) market is about 44 billion USD, with the top ten companies holding 80% of the market share.

Development of technology that meets market needs, along with collaboration with international companies, is required.

4. Technical Advantages

SG Cap™ captures large amounts of chemicals or macromolecules in their natural conformation, in an active orientation, and without the need for affinity-tag modifications.

SG Cap™ can immobilize 100X more protein than competing 2D surfaces. Because molecules are captured instead of bound, many more functional groups and epitopes on the immobilized molecule are biochemically available to capture targets.

These multiples increase the sensitivity and specificity of certain diagnostic assays and greatly improve the study of molecular interactions between drug-target, antigen-antibody and protein-aptamer pairs.

5. Technical Highlighted Summary

High specificity and sensitivity

SG Cap™ maintains the native conformations of embedded antigens or antibodies, increasing their specific activity and enabling 1000x greater sensitivity than that of current diagnostic technologies.

Multiplex capabilities

- Various markers for multiple diseases can be spotted in a single well.

- No interference response or cross reaction between spots

Low cost

Sol-gel and polymer substrate lowers the material cost to one sixth of conventional ELISA kit screening tests.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
The patent based SG CapTM was registered in South Korea in 2013 and applied in the USA, Europe, Brazil, India, Japan, and China.
FEATURED
Last Updated Jun 2016
Technology Type DIAGNOSTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE